|

AZD0120 Clinical Trials

6 actively recruiting trials across 5 locations

No change since May 2026

Also known as: GC012F

Pipeline

Phase 1: 2Phase 3: 1Phase 1/2: 3

Top Sponsors

  • AstraZeneca5
  • Alexion Pharmaceuticals, Inc.1

Indications

  • Cancer4
  • Relapsed/ Refractory Multiple Myeloma2
  • Systemic Sclerosis1
  • Lupus Erythematosus, Systemic1
  • Light Chain Amyloidosis1

Phoenix, Arizona2 trials

A Phase 1b/2 Study of CAR T Cell Therapy Targeting CD19 and BCMA in Participants With Relapsed or Refractory AL Amyloidosis.

Research Site

Phase 1/2
A Phase I, Open-label, Multicenter Study to Evaluate the Safety, Tolerability, Cellular Kinetics, Immunogenicity, Pharmacodynamics, and Preliminary Efficacy of AZD0120 in Participants With Multiple Myeloma (DURGA-2)

Research Site

Phase 1

Birmingham, Alabama1 trial

AZD0120 in Relapsed/Refractory Multiple Myeloma (DURGA-1)

Research Site

Phase 1/2

Gilbert, Arizona1 trial

A Study Comparing AZD0120, a Dual-targeted CAR-T Against B-cell Maturation Antigen (BCMA) and CD19, Versus Standard Regimens in Participants With Relapsed Refractory Multiple Myeloma (DURGA-4)

Research Site

Phase 3

Tucson, Arizona1 trial

A Study of AZD0120 in Autoimmune Diseases

Research Site

Phase 1

San Francisco, California1 trial

A Study to Investigate the Safety, Tolerability, and Efficacy of AZD0120 in Adults With Refractory SLE

Research Site

Phase 1/2

Trial data from ClinicalTrials.gov. Trial status and eligibility can change — verify directly with the study contact or on ClinicalTrials.gov.

This site does not provide medical advice. Always consult your doctor before considering enrollment in a clinical trial. Learn more on our About page.